SEHK:2576Life Sciences
Taimei Medical (SEHK:2576) Losses Narrow Sharply In 1H FY 2025 Challenging Bearish Narratives
Zhejiang Taimei Medical Technology (SEHK:2576) has reported its FY 2025 first half results with revenue of ¥244.2 million and a basic EPS loss of ¥0.04, compared with FY 2024 first half revenue of ¥272.8 million and a basic EPS loss of ¥0.32. Over the trailing twelve months to the second half of 2025, revenue has ranged between ¥512.5 million and ¥573.1 million while basic EPS losses have moved between ¥0.08 and ¥0.64. This gives investors a clearer view of how the top line and per share...